Mesenchymal stem cells alleviate TNBS-induced colitis by modulating inflammatory and autoimmune responses
Qian-Qian Chen1, Li Yan, Chang-Zheng Wang
1Department of Gastroenterology, Chinese PLA General Hospital, Medical College of PLA, Beijing 100853, China.
World Journal of Gastroenterology
|August 8, 2013
Summary
Mesenchymal stem cells (MSCs) show therapeutic potential for inflammatory bowel disease (IBD). Transplanted MSCs reduced colitis severity, promoted intestinal healing, and modulated immune responses, suggesting their use in cell-based IBD therapy.
Area of Science:
- Immunology
- Gastroenterology
- Regenerative Medicine
Background:
- Inflammatory bowel disease (IBD) encompasses chronic inflammatory conditions of the gastrointestinal tract.
- Current treatments for IBD have limitations and significant side effects.
- Mesenchymal stem cells (MSCs) possess immunomodulatory and regenerative properties with therapeutic potential.
Purpose of the Study:
- To evaluate the efficacy of bone marrow mesenchymal stem cells (BMSCs) in an experimental model of inflammatory bowel disease (IBD).
- To investigate the underlying mechanisms of MSC-mediated therapeutic effects in colitis.
- To assess the impact of MSC transplantation on immune cell populations and inflammatory mediators.
Main Methods:
- An experimental colitis model was induced in mice using trinitrobenzene sulfonic acid (TNBS).
- Bone marrow mesenchymal stem cells (BMSCs) from GFP-transgenic mice were intravenously transplanted after disease onset.
- Clinical scores, histological changes, cell tracking (GFP/SRY), proliferation markers (Ki67, Lgr5), and inflammatory cytokine profiles (TNF-α, IFN-γ, IL-2, IL-6, IL-17, IL-4, IL-10, TGF-β) were assessed.
Main Results:
- BMSC transplantation significantly ameliorated colitis severity, improved clinical outcomes, and increased survival rates.
- MSCs homed to the injured colon and promoted intestinal epithelial cell proliferation and stem cell differentiation.
- Therapeutic effects were mediated by down-regulation of Th1/Th17 responses and up-regulation of Th2 and regulatory T cell (Treg) activities.
Conclusions:
- Mesenchymal stem cells (MSCs) demonstrate significant therapeutic potential for inflammatory bowel disease (IBD).
- MSCs modulate immune and inflammatory responses, promoting intestinal healing and immune tolerance.
- MSC-based therapy represents a promising avenue for treating IBD.
Keywords:
ImmunomodulationInflammatory bowel diseaseInflammatory responseMesenchymal stem cellsTherapyTransplantationTrinitrobenzene sulfonic acid colitisMore Related Videos
Related Concept Videos
01:19Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:28Inflammatory Response
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...